ADAG | Adagene Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.8900 - 2.0675
52 Week Range	1.6000 - 4.38
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	36,873
Average Volume	61,992
Shares Outstanding	44,270,784
Market Cap	90,755,107
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-02-09

Valuation
Profitability
Growth
Health
P/E Ratio	-2.81
Forward P/E Ratio	N/A
EPS	-0.73
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	174
Country	China
Website	ADAG

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.

ADAG's peers: AADI, ACXP, AVTE, ACRV, RZLT, ANTX, ANEB, ANAB, MLYS, ELYM, JANX, PMVP, MOLN, ADVM, ALVR, ALZN, ANIX, APRE, ATXS, AURA, BCAB, BCDA, BCYC, BNOX, CADL, PTIX, CDMO, CDXC, CELC, CING, CSBR, GNFT, GNTA, IMNM, LVTX, MNOV, MNPR, MRUS, OPT, SLGL, VERA, XLO, BLTE, IRON

*Chart delayed

Analyzing fundamentals for ADAG we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see ADAG Fundamentals page.

Watching at ADAG technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ADAG Technicals page.